Ionis Pharmaceuticals, Inc. (IONS)
|Net Income (ttm)||-541.96M|
|Day's Range||29.81 - 30.53|
|52-Week Range||29.01 - 64.37|
|Price Target||54.94 (+80.5%)|
|Est. Earnings Date||Nov 3, 2021|
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclero... [Read more...]
Financial PerformanceFinancial Statements
According to 20 analysts, the average rating for IONS stock is "Buy." The 12-month stock price forecast is 54.94, which is an increase of 80.49% from the latest price.
An experimental treatment for amyotrophic lateral sclerosis missed the mark in a phase 3 trial.
CARLSBAD, Calif., Oct. 20, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, November 3 rd at 11:30 a.m.
The stock price of Ionis Pharmaceuticals, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, plunged 14% in yesterday's trade to its five year low levels of $30,...
CARLSBAD, Calif., Oct. 17, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) partner Biogen today announced topline results from its placebo-controlled pivotal Phase 3 VALOR study of tofer...
These stocks could be attractive at discounted prices.
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting
CARLSBAD, Calif., Sept. 3, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today it will present 14 posters and two symposiums highlighti...
CARLSBAD, Calif., Sept. 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present a company overview at the following virtual investor conferences: ...
Ionis (IONS) incurs wider-than-expected Q2 loss. The company maintains its sales guidance for 2021 but expects to incur more losses.
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -1.79% and -9.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
CARLSBAD, Calif., Aug. 4, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the second quarter of 2021 and recent business achievements.
CARLSBAD, Calif., July 29, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced it has completed enrollment of NEURO-TTRansform, the com...
Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC
CAMBRIDGE, Mass. and CARLSBAD, Calif.
These biotech stocks could have great long-term potential.
CARLSBAD, Calif., July 21, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, August 4 th at 11:30 a.m.
Ionis (IONS) signs a deal with Bicycle Therapeutics to incorporate the latter's optimized Bicycle peptides into its LICA delivery platform.
Bicycle Therapeutics plc (NASDAQ: BCYC) announced that Ionis Pharmaceuticals Inc (NASDAQ: IONS) has exercised its option and entered into an exclusive worldwide license and collaboration agreement to de...
Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology
CARLSBAD, Calif., July 13, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ...
You can get a lot of bang for the buck with these picks.
Recent trial disappointments scared off some investors.
We believe that the stock price of Ionis Pharmaceuticals, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, is undervalued at current levels of under $37. IONS ...